Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR
 system as measured by rates of all-cause mortality or disabling stroke at two years is
 noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low
 predicted risk of operative mortality for SAVR.

 The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial
 protocol is to conclude the randomized phase of the trial and initiate the single-arm,
 non-randomized, continued access phase of the trial.
Multi-center, international, prospective, randomized, interventional, pre-market.

 Subjects will be randomized on 1:1 basis to either TAVR with the Medtronic TAVR system or to
 SAVR. Patients will be seen at pre and post-procedure, discharge, 30 days, 6 months, 1 year,
 18 months, and annually through 10 years.

 The expanded use addendum is a multi-center, prospective, non-randomized continued access
 trial. All heart team approved subjects will be assigned to TAVR with the Medtronic TAVR
 system. Patients will be seen at pre and post-procedure, discharge, 30 days, and annually
 through 10 years. Enrollment is expected not to exceed 3660 attempted implants in the United
 States.
Inclusion Criteria:

 1. Severe aortic stenosis, defined as follows:

 1. For symptomatic patients:

 Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean
 gradient ≥40 mmHg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic
 echocardiography at rest

 2. For asymptomatic patients:

 -  Very severe aortic stenosis with an aortic valve area of ≤1.0 cm2 (or aortic
 valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec ,
 or mean gradient ≥60 mmHg by transthoracic echocardiography at rest, OR

 -  Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2),
 AND a mean gradient ≥40 mmHg or maximal aortic valve velocity ≥4.0 m/sec by
 transthoracic echocardiography at rest, AND an exercise tolerance test that
 demonstrates a limited exercise capacity, abnormal BP response, or
 arrhythmia OR

 -  Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2),
 AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by
 transthoracic echocardiography at rest, AND a left ventricular ejection
 fraction <50%.

 2. Documented heart team agreement of low risk for SAVR, where low risk is defined as
 predicted risk of mortality for SAVR <3% at 30 days per multidisciplinary local heart
 team assessment.

 3. The subject and the treating physician agree that the subject will return for all
 required post-procedure follow-up visits.

 Exclusion Criteria:

 1. Any condition considered a contraindication for placement of a bioprosthetic valve
 (eg, subject is indicated for mechanical prosthetic valve).

 2. A known hypersensitivity or contraindication to any of the following that cannot be
 adequately pre-medicated:

 1. aspirin or heparin (HIT/HITTS) and bivalirudin

 2. ticlopidine and clopidogrel

 3. Nitinol (titanium or nickel)

 4. contrast media

 3. Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), thrombocytopenia (platelet
 count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or
 hypercoagulable states.

 4. Ongoing sepsis, including active endocarditis.

 5. Any percutaneous coronary or peripheral interventional procedure with a bare metal
 stent within 30 days prior to randomization, or drug eluting stent performed within
 180 days prior to randomization.

 6. Multivessel coronary artery disease with a Syntax score >22 and/or unprotected left
 main coronary artery.

 7. Symptomatic carotid or vertebral artery disease or successful treatment of carotid
 stenosis within 10 weeks of Heart Team assessment.

 8. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
 mechanical hemodynamic support.

 9. Recent (within 2 months of Heart Team assessment) cerebrovascular accident (CVA) or
 transient ischemic attack (TIA).

 10. Gastrointestinal (GI) bleeding that would preclude anticoagulation.

 11. Subject refuses a blood transfusion.

 12. Severe dementia (resulting in either inability to provide informed consent for the
 trial/procedure, prevents independent lifestyle outside of a chronic care facility, or
 will fundamentally complicate rehabilitation from the procedure or compliance with
 follow-up visits).

 13. Estimated life expectancy of less than 24 months due to associated non-cardiac
 co-morbid conditions.

 14. Other medical, social, or psychological conditions that in the opinion of the
 investigator precludes the subject from appropriate consent or adherence to the
 protocol required follow-up exams.

 15. Currently participating in an investigational drug or another device trial (excluding
 registries).

 16. Evidence of an acute myocardial infarction ≤30 days before the trial procedure due to
 unstable coronary artery disease (WHO criteria).

 17. Need for emergency surgery for any reason.

 18. Subject is pregnant or breast feeding.

 19. Subject is less than legal age of consent, legally incompetent, or otherwise
 vulnerable

 20. Pre-existing prosthetic heart valve in any position.

 21. Severe mitral regurgitation amenable to surgical replacement or repair.

 22. Severe tricuspid regurgitation amenable to surgical replacement or repair.

 23. Moderate or severe mitral stenosis amenable to surgical replacement or repair.

 24. Hypertrophic obstructive cardiomyopathy with left ventricular outflow gradient.

 25. Bicuspid aortic valve verified by echocardiography, MDCT, or MRI.

 26. Prohibitive left ventricular outflow tract calcification.

 27. Sinus of Valsalva diameter unsuitable for placement of the self-expanding
 bioprosthesis.

 28. Aortic annulus diameter of <18 or >30 mm.

 29. Significant aortopathy requiring ascending aortic replacement.

 For transfemoral or transaxillary (subclavian) access:

 30. Access vessel mean diameter <5.0 mm for Evolut 23R, 26R, or 29R mm TAV, or access
 vessel mean diameter <5.5 mm for Evolut 34R mm or Evolut PRO TAV. However, for
 transaxillary (subclavian) access in patients with a patent LIMA, access vessel mean
 diameter <5.5mm for Evolut 23R, 26R, or 29R mm TAV, or access vessel mean diameter
 <6.0 mm for the Evolut 34R or Evolut PRO TAV.